| Literature DB >> 22226453 |
Ulrich Weber1, Robert Gw Lambert, Kaspar Rufibach, Walter P Maksymowych, Juerg Hodler, Anna Zejden, Stefan Duewell, Rudolf O Kissling, Paul L Filipow, Anne G Jurik.
Abstract
INTRODUCTION: Inflammatory involvement of the anterior chest wall (ACW) affects the quality of life of patients with spondyloarthritis (SpA), although involvement of the ACW is often neglected on clinical and imaging evaluation. Whole-body (WB) MRI is an imaging method used to assess the ACW in addition to the sacroiliac joints and spine without inconvenience for patients. Our goals in this study were to describe the distribution of ACW inflammation by WB MRI in both early and established SpA and associations between clinical and imaging findings indicative of inflammation.Entities:
Mesh:
Year: 2012 PMID: 22226453 PMCID: PMC3392789 DOI: 10.1186/ar3551
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Inflammatory lesions of the anterior chest wall displayed by whole-body MRI in an AS patient complaining about chest wall pain. Bone marrow edema (arrows) in both parts of the manubriosternal joint on coronal and sagittal short τ inversion recovery (STIR) sequences in a 46-year-old human leukocyte antigen B27 (HLA-B27)-positive male patient with ankylosing spondylitis and anterior chest wall pain. He had a 6-year history of inflammatory back pain. The arrowheads point to the mammary veins.
Figure 2MRI inflammation of the anterior chest wall in an AS patient without clinical signs of chest wall involvement. Bone marrow edema (dashed arrows) of the fourth and fifth right sternocostal joints on frontal and sagittal STIR sequences in a 26-year-old HLA-B27-positive female patient with ankylosing spondylitis but no anterior chest wall pain. The patient reported a 2-year history of inflammatory back pain. Bone marrow edema is also seen in the lower portion of the manubriosternal joint on the left side (arrow). The mammary veins are indicated by arrowheads.
Characteristics of the study subjectsa
| Variable | SpA group | AS group | nrSpA group | Control group |
|---|---|---|---|---|
| Male:female ratio (% male) | 90:32 (73.8) | 73:22 (76.8) | 17:10 (63.0) | 42:33 (56.0) |
| Age, years | 33.8 [17.3 to 71.6] | 35.7 [17.3 to 71.6] | 27.0 [18.8 to 44.8] | 30.3 [17.7 to 63.8] |
| Symptom duration, years | 7.0 [0.3 to 41.0] | 11.0 [0.3 to 41.0] | 1.2 [0.3 to 5.0] | N/A |
| HLA-B27-positive, | 105/120 (87.5) | 81/93 (87.1) | 24/27 (88.9) | N/A |
| BASDAI, NRS range 0 to 10 | 4.4 [0.4 to 9.0] | 4.6 [0.4 to 9.0] | 3.9 [0.8 to 6.3] | N/A |
| BASFI, NRS range 0 to 10 | 2.9 [0 to 8.2] | 3.2 [0 to 7.8] | 2.1 [0 to 8.2] | N/A |
| BASMI, NRS range 0 to 10 | 1.0 [0 to 8.0] | 1.0 [0 to 8.0] | 0 [0 to 4.0] | N/A |
| CRP level, mg/L | 5.0 [0 to 150.0] | 5.0 [0 to 57.0] | 3.0 [0 to 150.0] | N/A |
| ESR (mm/hour) | 12.5 [1.0 to 72.0] | 14.0 [2.0 to 69.0] | 8.5 [1.0 to 72.0] | N/A |
aAS = ankylosing spondylitis; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index [23]; BASFI = Bath Ankylosing Spondylitis Functional Index [24]; BASMI = Bath Ankylosing Spondylitis Metrology Index [25]; CRP = C-reactive protein, reference range ≤5 mg/L; ESR = erythrocyte sedimentation rate; HLA-B27 = human leukocyte antigen B27; N/A = not applicable; NRS = numeric rating scale; nrSpA = nonradiographic axial spondyloarthritis; SpA = spondyloarthritis. bHLA-B27 was not tested in two patients in the AS group. Values for the continuous demographic and clinical variables are medians [IQR] unless otherwise stated.
Clinical anterior chest wall inflammation by patient and physician assessment and concordance between the two assessmentsa
| Assessments | SpA group | AS group | nrSpA group |
|---|---|---|---|
| Patient assessment, | 73 | 58 | 15 |
| ACW pain present, | 19 (26.0%) | 16 (27.6%) | 3 (20.0%) |
| Physician assessment, | 122 | 95 | 27 |
| ACW tenderness present, | 32 (26.2%) | 25 (26.3%) | 7 (25.9%) |
| Patient versus physician assessmentb (SpA group) | ACW tenderness present | ACW tenderness absent | Total |
| ACW pain present, | 12 (16.4%) | 7 (9.6%) | 19 (26.0%) |
| ACW pain absent, | 7 (9.6%) | 47 (64.4%) | 54 (74.0%) |
| Total, | 19 (26.0%) | 54 (74.0%) | 73 (100%) |
aACW = anterior chest wall; AS = ankylosing spondylitis; nrSpA = nonradiographic spondyloarthritis; SpA = spondyloarthritis. bEstimated Cohen's κ = 0.50 (95% CI = 0.24 to 0.71).
Frequency of MRI-detected lesions recorded concordantly by the majority of readers (at least four of seven) for each joint and per subjecta
| Variables | SpA group | AS group | nrSpA group | Control group |
|---|---|---|---|---|
| SClJ bone marrow edema | 29 (23.8%) | 26 (27.4%) | 3 (11.1%) | 1 (1.3%) |
| SClJ erosion | 14 (11.5%) | 13 (13.7%) | 1 (3.7%) | 2 (2.7%) |
| SClJ fat infiltration | 13 (10.7%) | 13 (13.7%) | 0 (0%) | 1 (1.3%) |
| SClJ synovitis | 16 (13.1%) | 13 (13.7%) | 3 (11.1%) | 1 (1.3%) |
| MSJ bone marrow edema | 41 (33.6%) | 35 (36.8%) | 6 (22.2%) | 6 (8.0%) |
| MSJ erosion | 37 (30.3%) | 31 (32.6%) | 6 (22.2%) | 7 (9.3%) |
| MSJ fat infiltration | 25 (20.5%) | 24 (25.3%) | 1 (3.7%) | 3 (4.0%) |
| MSJ fusion | 14 (11.5%) | 14 (14.7%) | 0 (0%) | 0 (0%) |
| SCoJ bone marrow edema | 8 (6.6%) | 8 (8.4%) | 0 (0%) | 0 (0%) |
| SCoJ erosion | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| SCoJ fat infiltration | 4 (3.3%) | 4 (4.2%) | 0 (0%) | 0 (0%) |
| ACW bone marrow edema (≥1 joint) | 54 (44.3%) | 47 (49.5%) | 7 (25.9%) | 7 (9.3%) |
| ACW erosion (≥1 joint) | 42 (34.4%) | 35 (36.8%) | 7 (25.9%) | 9 (12.0%) |
| ACW fat infiltration (≥1 joint) | 33 (27.0%) | 32 (33.7%) | 1 (3.7%) | 4 (5.3%) |
| ACW ≥1 of 5 lesionsb (≥1 joint) | 72 (59.0%) | 62 (65.3%) | 10 (37.0%) | 15 (20.0%) |
aACW = anterior chest wall; AS = ankylosing spondylitis; MSJ = manubriosternal joint; nrSpA = nonradiographic axial spondyloarthritis; SClJ = sternoclavicular joint; SCoJ = sternocostal joint; SpA = spondyloarthritis. bBone marrow edema ACW and/or erosion ACW, fat infiltration ACW, synovitis SClJ, fusion MSJ. The number of patients with MRI-detected lesions in the entire ACW may be lower than the addition of patients with MRI changes of the three joints SClJ, MSJ and SCoJ, because some patients showed inflammation in more than one joint. Values are the number of subjects (percentage).
Agreement between clinical assessments and MRI-detected lesions of the anterior chest wall indicative of inflammationa
| Patient group | |||
|---|---|---|---|
| ACW tenderness | BME | SpA | 0.06 [0.00 to 0.20] |
| AS | 0.14 [0.06 to 0.20] | ||
| nrSpA | -0.10 [-0.31 to 0.29] | ||
| Erosion | SpA | -0.03 [-0.11 to 0.01] | |
| AS | -0.03 [-0.11 to 0.03] | ||
| nrSpA | -0.06 [-0.18 to 0.19] | ||
| Fat infiltration | SpA | 0.04 [-0.04 to 0.15] | |
| AS | 0.09 [-0.04 to 0.18] | ||
| nrSpA | -0.20 [-0.23 to 0.15] | ||
| ACW pain | BME | SpA | 0.21 [0.06 to 0.29] |
| AS | 0.18 [0.03 to 0.28] | ||
| nrSpA | 0.33 [0.17 to 0.44] | ||
| Erosion | SpA | -0.09 [-0.18 to 0.17] | |
| AS | -0.12 [-0.25 to 0.17] | ||
| nrSpA | 0.17 [-0.11 to 0.29] | ||
| Fat infiltration | SpA | 0.10 [-0.14 to 0.19] | |
| AS | 0.06 [-0.22 to 0.19] | ||
| nrSpA | 0.17 [0.07 to 0.44] |
aACW = anterior chest wall; AS = ankylosing spondylitis; BME = bone marrow edema; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score [16]; nrSpA = nonradiographic spondyloarthritis; SpA = spondyloarthritis. bACW tenderness in at least one of four MASES points (physician assessment); ACW pain indicated by patients on a manikin form (patient assessment). cMRI-detected lesion recorded in at least one of eight ACW joint locations by each of the seven readers. dMedian Cohen's κ values [range] of all seven individual readers.